SynapCell
SynapCell is a leader in preclinical efficacy testing in CNS disorders, supporting international biopharmaceutical companies in identifying their most promising candidates. The translational, objective EEG endpoints we have characterize in translational animal models in vivo have enabled our clients to unlock the true potential of their drugs. Our areas of expertise span from epilepsy to neuropsychiatry and movement disorders. We strongly believe that regular back and-forth interactions with Sponsor throughout the project is the key to make the most out of an experiment and deliver clear, comprehensive information to help our clients decide on a GO/NO GO decision towards the clinic.
